Treatment of uterine papillary serous carcinoma

Bibliography

• Siegel R, Naishadham D, Jemal A. Cancer statistics 2013. CA Cancer J Clin 2013;63:11-30
   PubMed Web of Science ®Google Scholar
• Hendrickson M, Ross J, Eifel P, et al. Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma. Am J Surg Pathol 1982;6(2):93-108
   PubMed Web of Science ®Google Scholar
• Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 1982;1591:10-17
   Google Scholar
• Ko E, Franasiak J, Sink K, et al. Obesity, diabetes and race in type I and type II endometrial cancers. 2012 ASCO Annual Meeting; June 2012; Chicago IL. J Clin Oncol 2011;29(Suppl):abstract 5111
   Google Scholar
• Maxwell GL, Tian C, Risinger J, et al. Racial disparity in survival among patients with advanced/recurrent endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2006;107(9):2197-205
   Google Scholar
• Gehrig PA, Bae-Jump VL, Boggess JF, et al. Association between uterine serous carcinoma and breast cancer. Gynecol Oncol 2004;94(1):208-11
   PubMedGoogle Scholar
• Chan JK, Manuel MR, Cheung MK, et al. Breast cancer followed by corpus cancer: is there a higher risk for aggressive histologic subtypes? Gynecol Oncol 2006;102(3):508-12
   PubMedGoogle Scholar
• Pennington KP, Walsh T, Lee M, et al. BRCA1, TP53, and CHEK2 germline mutations in uterine serous carcinoma. Cancer 2013;119(2):332-8
   PubMedGoogle Scholar
• Lavie O, Hornreich G, Ben-Arie A, et al. BRCA germline mutations in Jewish women with uterine serous papillary carcinoma. Gynecol Oncol 2004;92:521
   PubMed Web of Science ®Google Scholar
• Biron-Shental T, Drucker L, Altaras M, et al. High incidence of BRCA1-2 germline mutations, previous breast cancer and familial cancer history in Jewish patients with uterine serous papillary carcinoma. Eur J Surg Oncol 2006;32:1097
   PubMed Web of Science ®Google Scholar
• Creasman WT, Odicino F, Maisonneuve P, et al. Carcinoma of the corpus uteri. FIGO 26th annual report on the results of treatment in gynecologic cancer. Int J Gynaecol Obstet 2006;94:642
   Google Scholar
• Hamilton CA, Cheung MK, Osann K, et al. Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers. Br J Cancer 2006;94:642
   PubMed Web of Science ®Google Scholar
• Huang GS, Gebb JS, Einstein MH, et al. Accuracy of preoperative endometrial sampling for the detection of high-grade endometrial tumors. Am J Obstet Gynecol 2007;196:243; e1
   PubMed Web of Science ®Google Scholar
• Shaznik-Wikiel ME, Ueda SM, Frasure HE, et al. Abnormal cervical cytology in the diagnosis of uterine papillary serous carcinoma: earlier detection of a poor prognostic cancer subtype? Acta Cytol 2011;55:255-60
   PubMedGoogle Scholar
• Gupta D, Gunter MJ, Yang K, et al. Performance of serum CA-125 as a prognostic biomarker in patients with uterine papillary serous carcinoma. Int J Gynecol Cancer 2011;21:529
   PubMedGoogle Scholar
• Olawaiye AB, Rauh-Hain JA, Withiam-Leitch M, et al. Utility of pre-operative serum CA-125 in the management of uterine papillary serous carcinoma. Gynecol Oncol 2008;110:293
   PubMed Web of Science ®Google Scholar
• Moller KA, Gehrig PA, Van Le L, et al. The role of optimal debulking in advanced stage serous carcinoma of the uterus. Gynecol Oncol 2004;94:170
   PubMed Web of Science ®Google Scholar
• Bristow RE, Duska LR, Montz FJ. The role of cytoreductive surgery in the management of stage IV uterine papillary serous carcinoma. Gynecol Oncol 2001;81:92
   PubMed Web of Science ®Google Scholar
• Thomas MB, Mariani A, Cliby WA, et al. Role of cytoreductive surgery in stage III and IV uterine papillary serous carcinoma. Gynecol Oncol 2007;107:190
   PubMed Web of Science ®Google Scholar
• Despierre E, Moerman P, Vergote I, Amant F. Is there a role for neoadjuvant chemotherapy in the treatment of stage IV serous endometrial carcinoma? Int J Gynecol Cancer 2006;16(Suppl 1):273-7
   PubMedGoogle Scholar
• Le TD, Yamada SD, Rutgers JL, DiSaia PJ. Complete response of a stage IV uterine papillary serous carcinoma to neoadjuvant chemotherapy with Taxol and carboplatin. Gynecol Oncol 1999;73(3):123-7
   Google Scholar
• Fader AN, Starks D, Rose PG, et al. Percentage UPSC, lymphovascular invasion, and tumor size are not independent predictors of recurrence. Gynecol Oncol 2009;112(2 Suppl 1):S72
   Google Scholar
• Slomovitz BM, Burke TW, Eifel PJ, et al. Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases. Gynecol Oncol 2003;91:463-9
   PubMed Web of Science ®Google Scholar
• Carcangiu ML, Tan LK, Chambers JT. Stage 1A uterine serous carcinoma: a study of 13 cases. Am J Surg Pathol 1997;21(12):1507-14
   PubMedGoogle Scholar
• Gehrig PA, Groben PA, Fowler WC Jr, et al. Noninvasive papillary serous carcinoma of the endometrium. Obstet Gynecol 2001;97(1):153-7
   PubMedGoogle Scholar
• Goff BA, Kato D, Schmidt RA, et al. Uterine papillary serous carcinoma: patterns of metastatic spread. Gynecol Oncol 1994;54(3):264-8
   PubMed Web of Science ®Google Scholar
• Turner BC, Knisely JP, Kacinski BM, et al. Effective treatment of stage I uterine papillary serous carcinoma of the endometrium. Gynecol Oncol 2003;90(1):181-5
   PubMedGoogle Scholar
• Gehrig PA, Van Le L, Fowler WC Jr. The role of omentectomy during the surgical staging of uterine serous carcinoma. Int J Gynecol Cancer 2003;13(2):212-5
   PubMedGoogle Scholar
• Kitchener H, Swart AM, Qian Q, et al. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MR ASTEC trial): a randomized study. Lancet 2009;373(9658):125-36
   PubMed Web of Science ®Google Scholar
• Todo Y, Kato H, Kaneuchi M, et al. Survival effect of para-aortic lymphadenectomy in endometrial cancer (SEPAL study): a retrospective cohort analysis. Lancet 2010;375:1165-72
   PubMed Web of Science ®Google Scholar
• Moore KN, Fader AN. Uterine papillary serous carcinoma. Clin Obstet Gynecol 2011;54(2):278-91
   PubMed Web of Science ®Google Scholar
• Fader AN, Boruta DM, Olawaiye AB, Gehrig PA. Uterine papillary serous cancer: a review of the literature. Gynecol Oncol 2012;127:651-61
   PubMedGoogle Scholar
• Kelly MG, O'Malley DM, Hui P, et al. Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy. Gynecol Oncol 2005;98:353-9
   PubMed Web of Science ®Google Scholar
• Elit L, Kwon J, Bentley J, et al. Optimal management for surgical stage I serous cancer of the uterus. Gynecol Oncol 2004;92:240-6
   PubMedGoogle Scholar
• Growdon WB, Rauh-Hain AJ, Cordon A, et al. Prognostic determinants in patients with stage I uterine papillary serous carcinoma. A 15-year multi-institutional review. Int J Gynecol Oncol 2012;22:417-24
   Google Scholar
• Sutton G, Axelrod JH, Bundy BN, et al. Adjuvant whole abdominal irradiation in clinical stages I and II papillary serous or clear cell carcinoma of the endometrium: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol 2006;100:349-54
   PubMedGoogle Scholar
• Kong A, Johnson N, Kitchener HC, Lawrie TA. Adjuvant radiotherapy for stage I endometrial cancer. Cochrane Database Syst Rev 2012;4:CD003916
   Google Scholar
• Huh WK, Powell M, Leah CA III, et al. Uterine papillary serous carcinoma: comparisons of outcomes in surgical stage I patients with and without adjuvant therapy. Gynecol Oncol 2003;91:470-5
   PubMed Web of Science ®Google Scholar
• Miller D, Filiaci V, Fleming G, et al. Randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2012;125:771
   Web of Science ®Google Scholar
• Einstein MH, Frimer M, Kuo DYS, et al. Phase II trial of adjuvant pelvic radiation “sandwiched” between combination paclitaxel and carboplatin in women with uterine papillary serous carcinoma. Gynecol Oncol 2012;124:21-5
   PubMed Web of Science ®Google Scholar
• Fader AN, Drake RD, O'Malley DM, et al. Platinum/Taxane-based chemotherapy with or without radiation therapy favorably impacts survival outcomes in stage I uterine papillary serous carcinoma. Cancer 2009;115(6):2119-27
   PubMedGoogle Scholar
• Kiess AP, Damast S, Makker V, et al. Five-year outcomes of adjuvant carboplatin/paclitaxel chemotherapy and intravaginal radiation for stage I-II papillary serous endometrial cancer. Gynecol Oncol 2012;127(2):321-5
   PubMed Web of Science ®Google Scholar
• Guintoli RL, Gerardi MA, Yemelyanova A, et al. Stage I noninvasive and minimally invasive uterine serous carcinoma: comprehensive staging associated with improved survival. Int J Gynecol Cancer 2012;22(2):273-9
   PubMedGoogle Scholar
• NCCN clinical practice guidelines in oncology. Uterine neoplasms, version 3.2012. National Comprehensive Cancer Network; 2012
   Google Scholar
• Boruta DM, Gehrig PA, Fader AN, Olawaiye AB. Management of women with uterine papillary serous cancer: a Society of Gynecologic Oncology (SGO) review. Gynecol Oncol 2009;115:142-53
   PubMed Web of Science ®Google Scholar
• Fader AN, Santin AD, Gehrig PA. Early stage uterine serous carcinoma: management updates and genomic advances. Gynecol Oncol 2013;129:244-50
   PubMed Web of Science ®Google Scholar
• Kwon J, Ackerman I, Franssen E. The role of abdominal-pelvic radiotherapy in the management of uterine papillary serous carcinoma. Int J Radiat Oncol Biol Phys 2004;59(5):1439-45
   PubMedGoogle Scholar
• Martinez AA, Weiner S, Podratz K, et al. Improved outcome at 10 years for serous-papillary/clear cell or high-risk endometrial cancer patients treated by adjuvant high-dose whole abdomino-pelvic irradiation. Gynecol Oncol 2003;90(3):537-46
   PubMedGoogle Scholar
• Sutton G, Axelrod JH, Bundy BN, et al. Whole abdominal radiotherapy in the adjuvant treatment of patients with stage III and IV endometrial cancer: a gynecologic oncology group study. Gynecol Oncol 2005;97(3):755-63
   PubMed Web of Science ®Google Scholar
• Randall ME, Filiaci VL, Muss H, et al. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a gynecologic oncology group study. Gynecol Oncol 2008;108(2):298-305
   PubMedGoogle Scholar
• Fleming GF, Brunetto VL, Cella D, et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a gynecologic oncology group study. J Clin Oncol 2004;15(8):2159-66
   Google Scholar
• Fleming GF, Filiaci VL, Bentley RC, et al. Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24h paclitaxel + filgrastim in endometrial carcinoma: a gynecologic oncology group study. Ann Oncol 2004;15(8):1173-8
   PubMed Web of Science ®Google Scholar
• Gallion HH, Brunetto VL, Cibull M, et al. Randomized phase III trial of standard timed doxorubicin plus cisplatin versus circadian timed doxorubicin plus cisplatin in stage III and IV or recurrent endometrial carcinoma: a gynecologic oncology group study. J Clin Oncol 2004;22(19):3808-13
   Google Scholar
• Thigpen JT, Brady MF, Homesley HD, et al. Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study. J Clin Oncol 2004;22(19):3902-8
   PubMed Web of Science ®Google Scholar
• Homesley HD, Filiaci V, Gibbons SK, et al. A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: a gynecologic oncology group study. Gynecol Oncol 2009;112(3):543-52
   PubMed Web of Science ®Google Scholar
• Hoskins PJ, Swenerton KD, Pike JA, et al. Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a phase II study. J Clin Oncol 2001;19(20):4048-53
   PubMed Web of Science ®Google Scholar
• Sovak MA, Hensley ML, Dupont J, et al. Paclitaxel and carboplatin in the adjuvant treatment of patients with high-risk stage III and IV endometrial cancer: a retrospective study. Gynecol Oncol 2006;103(2):451-7
   PubMedGoogle Scholar
• Vaidya AP, Littell R, Krasner C, Duska LR. Treatment of uterine papillary serous carcinoma with platinum-based chemotherapy and paclitaxel. Int J Gynecol Cancer 2006;16(Suppl 1):267-72
   PubMedGoogle Scholar
• Miller D, Filiaci V, Fleming G, et al. Randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: a Gynecologic Oncology Group study [abstract]. Gynecol Oncol 2012;125:771Y773
   Google Scholar
• Le Gallo M, O'Hara AJ, Rudd ML, et al. Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes. Nat Genet 2012;44:1310-15
   PubMed Web of Science ®Google Scholar
• Kuhn E, Wu RC, Guan B, et al. Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analysis. J Natl Cancer Inst 2012;104:1503-13
   PubMed Web of Science ®Google Scholar
• The Cancer Genome Atlas Research Network. Integrated genomic characterization of endometrial carcinoma. Nature 2013;497:67-73
   PubMed Web of Science ®Google Scholar
• Yarden Y, Sliwkowski MX. Untangling the erbB signaling network. Nat Rev Mol Cell Biol 2001;2(2):127-37
   PubMed Web of Science ®Google Scholar
• El Sahwi KS, Schwartz PE, Santin AD. Development of targeted therapy in uterine serous carcinoma, a biologically aggressive variant of endometrial cancer. Expert Rev Anticancer Ther 2012;12(1):41-9
   PubMedGoogle Scholar
• NIH Clinical trials. Evaluation of carboplatin/paclitaxel with or without trastuzumab (Herceptin) in uterine serous cancer. Available from: http://clinicaltrials.gov/ct2/show/; NCT01367002
   Google Scholar